Imago Raises $80m Series C To Take Bomedemstat Into Phase III
Company Plans IPO In 2021 To Fund Additional Pivotal Trials
Executive Summary
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.
You may also be interested in...
Inrebic Approval Is A Boost For Myelofibrosis And Celgene's Buyer Bristol
Investors in Impact Biosciences, which sold the selective JAK2 inhibitor to Celgene for $1.1bn up front, could double their money with milestone fees based on fedratinib's approval.
Finance Watch: Flagship Raises $824m To Speed Growth Of Its Portfolio Companies
Private Company Edition: The VC firm and start-up factory Flagship Pioneering brings in new cash for existing investments, tapping into investors eager to back "big, bold platform ideas" in the life sciences. Also, new financings include $100m-plus deals for Harmony and Beam.
BioNotebook: Five VC deals, three public financings, and a round of layoffs
Syros raises $53m Series B; Aileron gets $33m more for Series E; Imago closes $26.5m Series A; $20m equity investment for Xcovery; Affinivax launches with $4m; Synergy sells convertible notes; Regulus, Vanda price stock offerings; and Impax cuts 49 jobs.
Need a specific report? 1000+ reports available
Buy Reports